Flecainide Dosing for Ventricular Premature Complexes in Structurally Normal Hearts

Initial Dosing and Titration

• The American Heart Association recommends starting flecainide at 50 mg every 12 hours and titrating up to 100 mg every 12 hours if needed for efficacy, with a maximum dose of 300 mg/day for patients with ventricular premature complexes and structurally normal hearts 1
• Most patients achieve adequate suppression at doses between 100-200 mg twice daily (200-400 mg/day total), according to the American College of Cardiology 2, 3, 4

Maximum Dosing Limits and Safety Considerations

• The maximum recommended dose is 300 mg/day (150 mg twice daily) for paroxysmal supraventricular arrhythmias, as stated by the American Heart Association 1
• Flecainide is absolutely contraindicated in patients with structural heart disease, including ischemic heart disease, reduced left ventricular function, or history of myocardial infarction, according to the American College of Cardiology 1, 2, 3, 4

Monitoring and Dose Adjustment

• Obtain baseline ECG before starting therapy to document PR, QRS, and QTc intervals, as recommended by the American Heart Association 1
• Consider combining flecainide with AV nodal blocking agents (beta-blockers or calcium channel blockers) to prevent rapid ventricular response if atrial flutter develops, according to the American College of Cardiology 2, 3, 4

Critical Safety Considerations

• Before initiating therapy, confirm the absence of structural heart disease through appropriate cardiac evaluation, as stated by the European Society of Cardiology 6
• Monitor ECG for QRS widening—if QRS increases by >25% from baseline, reduce the dose or discontinue the drug, as recommended by the American Heart Association 1, 6